OverviewSuggest Edit

Aligos Therapeutics is a company that develops curative therapies for hepatologic diseases and viral infections. It discovers and develops compounds that interact with disease-causing molecules such as viral nucleic acids and their encoded proteins, as well as oncogenes and their resultant proteins.
TypePublic
Founded2018
HQSouth San Francisco, CA, US
Websitealigos.com

Latest Updates

Employees (est.) (Jun 2021)86(+29%)
Revenue (FY, 2020)$0
Share Price (Sept 2021)$16.2
Cybersecurity ratingCMore

Key People/Management at Aligos Therapeutics

Julian Symons

Julian Symons

Executive Vice President, Chief Scientific Officer
Sushmita M. Chanda

Sushmita M. Chanda

Executive Vice President, Translational Safety Sciences
John Fry

John Fry

Executive Vice President Clinical Development
Matthew W. McClure

Matthew W. McClure

Executive Vice President Chief Medical Officer
Lesley Ann Calhoun

Lesley Ann Calhoun

Executive Vice President Chief Financial Officer
David B. Smith

David B. Smith

Vice President Head of Chemical Operations
Show more

Aligos Therapeutics Office Locations

Aligos Therapeutics has offices in South San Francisco and Leuven
South San Francisco, CA, US (HQ)
1 Corporate Dr 2nd floor
Leuven, BE
Gaston Geenslaan 1/building 3
Show all (2)

Aligos Therapeutics Financials and Metrics

Aligos Therapeutics Revenue

USD

Net income (Q2, 2021)

(29.8m)

EBIT (Q2, 2021)

(29.6m)

Market capitalization (17-Sept-2021)

618.9m

Closing stock price (17-Sept-2021)

16.2

Cash (30-Jun-2021)

187.7m

EV

433.9m
Aligos Therapeutics's current market capitalization is $618.9 m.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

General and administrative expense

3.2m10.0m17.9m

R&D expense

10.5m44.0m79.9m

Operating expense total

13.7m54.0m108.4m
Half Year
USDH1, 2019H1, 2020

General and administrative expense

3.8m7.5m

R&D expense

17.3m34.5m

Operating expense total

21.1m42.0m

EBIT

(21.1m)(42.0m)
Quarterly
USDQ3, 2020Q1, 2021Q2, 2021

General and administrative expense

4.2m5.8m6.6m

R&D expense

17.3m22.9m24.6m

Operating expense total

33.3m28.8m31.3m

EBIT

(21.6m)(27.7m)(29.6m)
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

24.0m69.6m220.4m

Current Assets

92.4m120.2m250.0m

PP&E

2.9m8.5m8.0m

Total Assets

107.7m146.5m265.3m
Quarterly
USDQ2, 2020Q3, 2020Q1, 2021Q2, 2021

Cash

22.7m31.8m200.4m187.7m

Current Assets

91.5m73.7m219.8m196.6m

PP&E

9.0m8.6m7.6m7.0m

Total Assets

107.9m92.2m234.5m211.9m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(13.9m)(52.3m)(108.5m)

Depreciation and Amortization

1.3m2.3m2.7m

Accounts Payable

3.0k385.0k(130.0k)

Cash From Operating Activities

(6.0m)(46.8m)(74.3m)
Quarterly
USDQ2, 2019Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Net Income

(20.0m)(40.8m)(74.1m)(27.7m)(57.5m)

Depreciation and Amortization

1.0m1.6m2.0m741.0k1.5m

Accounts Payable

732.0k(89.0k)3.7m(502.0k)(1.8m)

Cash From Operating Activities

(18.3m)(38.0m)(54.6m)(29.8m)(52.8m)
USDFY, 2018

Debt/Equity

-1 x

Debt/Assets

0.1 x

Financial Leverage

-7.8 x
Show all financial metrics

Aligos Therapeutics Operating Metrics

Q2, 2020

Discovery Projects

2

Pre-Clinical Phase Products

4

Phase I Trials Products

1
Show all operating metrics

Aligos Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Aligos Australia Pty LTD
Aligos Belgium BV

Aligos Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

Aligos Therapeutics Online and Social Media Presence

Embed Graph

Aligos Therapeutics News and Updates

Aligos Therapeutics to Announce Second Quarter 2021 Results August 5, 2021

SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company’s…

Aligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced the pricing of its underwritten public offering of 4,400,000 shares of common stock at a public offering price of $19.00 per share. In addition, Aligos has granted the underwrite…

Aligos Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common stock. In addition, Aligos intends to grant the underwriters a 30-day option to purchase up to…

Aligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of the Liver’s Digital International Liver Congress 2021

-Five scientific posters to be presented at upcoming EASL ILC meeting- All 4 Aligos CHB development candidates continue to advance – STOPS™ molecule and CAM drug candidates are currently being evaluated in CHB subjects - ASO and siRNA drug candidates are on track to enter clinical development in H2 …

Aligos Therapeutics to Present Preliminary Antiviral Activity of ALG-000184 in Chronic Hepatitis B (CHB) Subjects at HBV-TAG Conference

Subjects experienced a 2.9 log10 IU/mL mean reduction in HBV DNA levels after 14 days’ dosing with 100 mg ALG-000184

Aligos Therapeutics Appoints James Scopa, J.D., MBA, to its Board of Directors

SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has appointed J…
Show more

Aligos Therapeutics Frequently Asked Questions

  • When was Aligos Therapeutics founded?

    Aligos Therapeutics was founded in 2018.

  • Who are Aligos Therapeutics key executives?

    Aligos Therapeutics's key executives are Julian Symons, Sushmita M. Chanda and John Fry.

  • How many employees does Aligos Therapeutics have?

    Aligos Therapeutics has 86 employees.

  • Who are Aligos Therapeutics competitors?

    Competitors of Aligos Therapeutics include Nimbus Therapeutics, Metacrine and NorthSea Therapeutics.

  • Where is Aligos Therapeutics headquarters?

    Aligos Therapeutics headquarters is located at 1 Corporate Dr 2nd floor, South San Francisco.

  • Where are Aligos Therapeutics offices?

    Aligos Therapeutics has offices in South San Francisco and Leuven.

  • How many offices does Aligos Therapeutics have?

    Aligos Therapeutics has 2 offices.